Nearly three years of research have brought about remarkable results for the majority of 80 patients subjected to targeted alpha therapy of metastatic prostate cancer. The first assessments - ...
Earlier deployment of ARPIs, PARP inhibitors, and PSMA radioligand therapy yields deeper initial control but creates heavily pretreated mCRPC with complex resistance and cumulative toxicity ...
ORNL is a leader both in developing advanced radiotherapies and in providing the radioisotopes needed for those therapies.
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), ...
Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a side effect so debilitating that patients often refuse the life-saving ...
Up to 85 percent of prostate cancers are diagnosed in the early stages, when they are still curable.Even when diagnosed at an advanced stage, most prostate cancers respond well to treatment. The first ...
The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...
Tagawa, MD, identified 3 primary clinical scenarios where PSMA PET scans have become the established standard for prostate cancer care. The first application is initial s ...
State data from 2018 through 2022 shows prostate cancer is the leading cancer diagnosis in Cuyahoga County, yet 77% of cases ...
Germline testing can identify hereditary cancer, which leads to implications for family members, cascade testing for relatives, and starting surveillance and prevention measures: Genetic testing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results